Nectero Medical is developing the Nectero EAST System, an investigational single-use endovascular system that delivers pentagalloyl glucose (PGG) locally into the aneurysmal wall to bind elastin and collagen and potentially strengthen the aortic vessel wall. The procedure is performed in under an hour, leaves no permanent implant, and does not preclude future interventions; early clinical results from a first-in-human study were published in the Journal of Vascular Surgery. The company initiated a Phase II/III stAAAble trial in January 2024 to evaluate safety and efficacy in infrarenal AAAs (3.5–5.0 cm), and the Nectero EAST System received Fast Track and Breakthrough Therapy designations. Nectero positions the therapy as a potential first approved option for smaller AAAs beyond surveillance if trials are successful. The company cites a large addressable population (over 1M diagnosed Americans and ~60,000 treated annually) and will use recent financing to advance clinical work and regulatory submission. Its lead product aims to offer a minimally invasive alternative to current surveillance or treatments reserved for larger or symptomatic AAAs. Nectero Medical is developing the Endovascular Aortic Stabilization Treatment (EAST), a one-time catheter-based procedure that locally delivers a proprietary compound to stabilize small- to mid-sized aortic aneurysms and leave no implant behind. The EAST system has shown early clinical results and is currently treating AAA patients in a multi-site Phase 1 safety study. The therapy is intended to significantly reduce aneurysm growth rate, prevent rupture, and provide an option for patients who are managed with active surveillance or are ineligible for surgical repair. Proceeds from the recent financing will support in vivo and clinical trials to advance the platform. The company also cites potential broader applications including thoracic aneurysms, aortic dissections, neurovascular aneurysms, and other cardiovascular and connective tissue disorders. The company is based in Tempe, Ariz.

Total raised

$116M

Funding rounds

2

Latest round

Series D

Latest activity

Apr 2024